Avenue Therapeutics (NASDAQ:ATXI) Announces Earnings Results, Misses Expectations By $5.38 EPS

Avenue Therapeutics (NASDAQ:ATXI) released its earnings results on Friday. The company reported ($6.43) EPS for the quarter, missing the consensus estimate of ($1.05) by ($5.38), Zacks reports.

Avenue Therapeutics Stock Up 0.6 %

Shares of NASDAQ:ATXI traded up $0.02 during midday trading on Monday, reaching $2.49. The company’s stock had a trading volume of 32,123 shares, compared to its average volume of 67,814. The firm has a market cap of $2.34 million, a price-to-earnings ratio of -0.32 and a beta of -0.19. The business has a 50 day moving average price of $3.30 and a 200 day moving average price of $7.06. Avenue Therapeutics has a 1 year low of $2.25 and a 1 year high of $78.75.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders.